Comparison
Maridebart Cafraglutide vs. Pramlintid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
151126-32-8
Molecular weight
no data
3949.4 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Pramlintid
Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
0
of which in humans
1
0
Effects recorded
2
2
Open conflicts
0
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Maridebart Cafraglutide and Pramlintid?
- Maridebart Cafraglutide is classified as "Metabolic", while Pramlintid is classified as "Metabolic". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Maridebart Cafraglutide or Pramlintid?
- The highest available evidence level is "Human RCT" for Maridebart Cafraglutide and "Human RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Maridebart Cafraglutide and Pramlintid in Germany and the United States?
- Germany: Maridebart Cafraglutide — Unapproved, Pramlintid — Unapproved. United States: Maridebart Cafraglutide — Unapproved, Pramlintid — Prescription. These are factual summaries with source and review date on the individual pages.